AstraZeneca
NEWS
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
The new designation granted to Calquence marks the 10th such designation the company has earned since 2014, AstraZeneca said.
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Tagrisso improved overall survival in lung cancer patients.
Biopharma companies from across the globe share business and development updates.
AstraZeneca and Merck plan on seeking regulatory approval for Lynparza as a treatment for a subset of prostate cancer patients based on the Phase III PROfound data.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to AstraZeneca over its supplemental New Drug Application (sNDA) for Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes (T1D) when insulin alone doesn’t keep blood sugar levels under control.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
JOBS
IN THE PRESS